Alkem Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alkem Laboratories published its Q4 and FY2026 financial results in newspapers (The Economic Times, Business Standard, Mumbai Lakshadweep) as required under SEBI regulations. Consolidated total income grew 14.6% year-on-year to ₹36,033.2 million in Q4 and 13.5% to ₹1,47,122.7 million for FY26. Net profit after tax attributable to owners rose to ₹2,364.6 million for Q4 (vs ₹3,058.6 million in Q4 FY25) and ₹23,018.0 million for FY26 (vs ₹21,654.8 million in FY25), reflecting a 6.3% full-year increase. Basic EPS for FY26 stands at ₹192.51. Standalone revenue from continuing operations was ₹96,639.1 million. The Audit Committee reviewed the results on May 27, 2026, and the Board approved them on May 28, 2026, with auditors issuing an unmodified review report.
Steady full-year growth with revenue crossing ₹1.47 lakh crore and net profit at ₹23,018 million signals operational resilience. The modest Q4 net profit decline vs Q4 FY25 (₹2,364.6M vs ₹3,058.6M) may attract investor scrutiny on quarter-over-quarter performance.